Diagnostic Substances

(CLDX) From the Mailbag: Should You Dump Small Caps?

I’m sorry, James, but I can’t endorse your idea.

If you want to make money in the markets, small caps must be part of your portfolio. They outperform large caps over the long term and will add several percentage points to your overall return.

But small caps are risky, right?

On...

8Mar2014 | | Comments Off on (CLDX) From the Mailbag: Should You Dump Small Caps? | Continued

(AMAG) AMAG Pharmaceuticals Partner Takeda Pharmaceutical Recalls Batch of Rienso

AMAG Pharmaceuticals Inc. (AMAG) has been recently informed by partner, Takeda Pharmaceutical (TKPYY), that the latter is recalling a specific batch of Rienso from...

19Aug2013 | | Comments Off on (AMAG) AMAG Pharmaceuticals Partner Takeda Pharmaceutical Recalls Batch of Rienso | Continued

(OGXI) OncoGenex Pharmaceuticals’ OGX-427 Progresses

OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment of previously untreated advanced non-squamous non-small...

21Apr2013 | | Comments Off on (OGXI) OncoGenex Pharmaceuticals’ OGX-427 Progresses | Continued

(ABAX) Abaxis Incorporated Value Alert

Texas ( Mar. 04, 2013) Wax Ink has issued a No Investment Interest rating for Abaxis, Inc. (Nasdaq:

5Mar2013 | | Comments Off on (ABAX) Abaxis Incorporated Value Alert | Continued

(MYGN) Myriad Genetics Shares Upgraded to Outperform

Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), provider of molecular diagnostic products, to Outperform with a target price of $33.

Myriad started...

24Dec2012 | | Comments Off on (MYGN) Myriad Genetics Shares Upgraded to Outperform | Continued

(SRDX) SurModics Analyst Moves Shares Up to Outperform

We recently upgraded SurModics Inc. (SRDX) to Outperform from Neutral following its impressive results in the third quarter of fiscal 2012 (ended June 30, 2012). The stock carries a Zacks #2 Rank (Buy rating) in the short run.

SurModics’...

21Aug2012 | | Comments Off on (SRDX) SurModics Analyst Moves Shares Up to Outperform | Continued

(CEMI) Chembio Could Benefit From USPSTF Decision

USPSTF Decision Could Benefit CEMI

A Reuters article yesterday (8/19/2012) notes that health officials with apparent inside knowledge and speaking on condition of anonymity expect that the U.S. Preventative Services Task Force (USPSTF) will issue a draft recommendation by year-end...

21Aug2012 | | Comments Off on (CEMI) Chembio Could Benefit From USPSTF Decision | Continued

(NYMX) Nymox Pharmaceutical Sees Pipeline Progress

Nymox Pharmaceutical Corporation (NYMX) recently announced that it has completed enrollment of benign prostatic hyperplasia (BPH) patients in a phase III study (NX02-0020) of NX-1207 in the US. The study enrolled patients who were...

13Jul2012 | | Comments Off on (NYMX) Nymox Pharmaceutical Sees Pipeline Progress | Continued

(MYGN) Myriad Inks Deal with Cephalon

The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals (TEVA). ...

4Apr2012 | | Comments Off on (MYGN) Myriad Inks Deal with Cephalon | Continued

(ABAX) Abaxis Analyst Upgrades Shares to Neutral

Following the company’s solid second quarter 2011 results, which were ahead of the Zacks Consensus Estimates, we have upgraded our recommendation on Abaxis (ABAX) to Neutral with a target price of $26.00.

The company reported...

1Dec2011 | | 0 comments | Continued

(ABAX) Alere Takes Over Arriva Medical

Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has taken over Arriva Medical, a prominent vendor of diabetes testing supplies for patients residing...

1Dec2011 | | 0 comments | Continued

(SRDX) SurModics Analysts Cut Shares to Neutral

We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson & Johnson (JNJ) announced in June 2011 that it will...

10Jul2011 | | 0 comments | Continued

(BLUD) Company News for July 6, 2011 – Corporate Summary

•    Share prices of Southern Union Co. (NYSE:SUG) rose 4.21% to close at $42.07 after Energy Transfer Equity, L.P. (NYSE:ETE) increased its bidding amount by 21% to $5 billion for the company,...

6Jul2011 | | 0 comments | Continued

(BLUD) Immucor Purchased by TPG Capital for $1.9B

Manufacturer and seller of automated systems and reagents, Immucor Inc. (BLUD) recently announced that it will be taken over by private equity group TPG Capital for $1.97 billion. As per the terms of the agreement, Immucor’s shareholders...

6Jul2011 | | 0 comments | Continued

(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform

Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00.

Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting...

1Jul2011 | | 0 comments | Continued

(MYGN) Myriad Genetics – Bull of the Day

Myriad Genetics’ (MYGN) flagship product, Bracanalysis, has been recording robust growth over the past few quarters. Moreover, the company is undertaking strategies to expand the scope of the test. A strong cash balance enables...

1Jul2011 | | 0 comments | Continued

(AMAG) AMAG Pharmaceuticals Gets Label Update for Feraheme

AMAG Pharmaceuticals Inc. (AMAG) recently announced a label update for its lead drug Feraheme. Feraheme is an injectable drug for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia (IDA) in...

26Jun2011 | | 0 comments | Continued

(SRDX) SurModics Incorporated – Bull of the Day

In June 2011, SurModics, Inc. (SRDX) received a blow when Johnson & Johnson announced that it will stop manufacturing Cypher stents by year end, as SurModics receives royalties on sales of the product. However, we believe the...

21Jun2011 | | 0 comments | Continued

(AKRX) Company News for June 07, 2011 – Corporate Summary

•    Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011

•    According to Canaccord Genuity, data from a trial of Exelixis, Inc’s (NASDAQ:

7Jun2011 | | 0 comments | Continued

(VIVO) FDA OKs Meridian C. Difficile Test

Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH....

13May2011 | | 0 comments | Continued

(ABAX) Alere Quarterly Earnings Beats Estimates

Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, reported first-quarter fiscal 2011 adjusted earnings per share of 61 cents, beating the corresponding Zacks Consensus Estimate...

4May2011 | | 0 comments | Continued

(SRDX) SurModics Analyst Increases Shares to Outperform

We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Our target price on the stock is $18.00.

The company delivered strong results in the second...

4May2011 | | 0 comments | Continued

(SRDX) SurModics Incorporated – Bull of the Day

We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Adjusted earnings in the quarter came in at $0.08 per share, well ahead of break-even earnings suggested...

4May2011 | | 0 comments | Continued

(PBIO) Pressure BioSciences and KeraFAST Sign Worldwide E-Commerce Distribution Deal

Grant Zeng, CFA

PBIO and KeraFAST Sign Worldwide E-Commerce Distribution Deal

On May 3, 2011, Pressure BioSciences, Inc. (PBIO) and KeraFAST LLC announced that they have entered into...

3May2011 | | 0 comments | Continued

(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing

Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in...

9Apr2011 | | 0 comments | Continued

(TRIB) Trinity Biotech – Bull of the Day

Since its Q2 2010 clinical lab coag divestiture, Trinity Biotech (TRIB) has slashed operating costs and begun pumping its huge and growing cash balance into higher growth segments. Expectations are high for the PDX instrument, expected...

17Mar2011 | | 0 comments | Continued

(TRIB) Trinity Biotech – Bull of the Day

Since its Q2 2010 clinical lab coag divestiture, Trinity Biotech (TRIB) has slashed operating costs and begun pumping its huge and growing cash balance into higher growth segments. Expectations are high for the PDX instrument, expected...

13Mar2011 | | 0 comments | Continued

(SRDX) SurModics Analyst Maintains Neutral Rating on Shares

SurModics (SRDX), headquartered in Eden Prairie, Minnesota, is a provider of surface modification and drug delivery technologies to the healthcare industry. Following the changes in operational structure affected in 2008, the...

14Sep2010 | | 0 comments | Continued

(SRDX) SurModics Signs Deal With Australian company Clinuvel Pharmaceuticals

Recently, SurModics Inc. (SRDX) inked a licensing deal with Australian company Clinuvel Pharmaceuticals Limited. The deal allows SurModics’ pharmaceuticals unit, which provides proprietary polymer-based drug delivery technologies...

11Jul2010 | | 0 comments | Continued

(PBIO) Pressure Biosciences’ Technology on Display at Harvard Medical School Symposium

Harvard Medical School Symposium

On Friday, May 21, 2010, Harvard Medical School will host a symposium on the applications of ultra-high pressure in biotechnology. The full-day program focusing on the use of cycled ultra-high pressure (pressure cycling technology, or “PCT”)...

24May2010 | | 0 comments | Continued